guest ::
| Home > Publications database > Spatial heterogeneity of antibody-drug conjugate targets in pancreatic ductal adenocarcinoma. |
| Home > Publications database > Spatial heterogeneity of antibody-drug conjugate targets in pancreatic ductal adenocarcinoma. |
| Journal Article | DKFZ-2026-00619 |
; ; ; ; ; ; ; ; ; ;
2026
Wiley
Chichester
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease, with limited therapeutic options, few patients showing targetable molecular changes. New therapeutic strategies are necessary. Antibody-drug conjugates (ADCs) have emerged as alternative therapeutic strategies across various cancer types. Herein, we analyze the expression and spatial heterogeneity (six cores per patients) of three ADC targets (c-MET, NECTIN4, and TROP-2) in a cohort of 62 PDAC patients (1,116 tissue cores) and associate their levels with clinicopathological and genomic parameters, and the expression of immune checkpoints. c-MET exhibited significantly higher expression at the tumor front versus tumor center, along with notable intratumoral heterogeneity. In contrast, NECTIN4 and TROP-2 displayed homogeneous expression patterns, with NECTIN4 being absent in approximately two-thirds of cases, while TROP-2 showed consistently strong positivity across tumor regions (98% 3+). By simulating sampling sufficiency for reliable scoring, we observed that, for c-MET, two tumor samples were sufficient to achieve a maximum score of 1+, while for higher scores (2+ and 3+), four samples were required. For NECTIN4, four samples were necessary to detect scores of 1+ and 2+. For TROP-2, for a 3+ score, just two samples were sufficient to reach the maximum score. c-MET or TROP-2 expression scores were not associated with any clinicopathological parameters. In contrast, NECTIN4 expression showed an association with tumor grade. Correlations with immune checkpoints revealed that high TROP-2 expression was inversely correlated with PD-L1 expression. For all three markers no significant differences in expression were found between SMAD4 wild-type and SMAD4-mutated tumors, nor between TP53 wild-type and TP53-mutated tumors. Furthermore, analysis of lymph node and distant (liver and peritoneal) metastases revealed significantly higher c-MET and NECTIN4 expression in the metastatic setting. In conclusion, TROP-2 is highly expressed in most PDACs, independent of clinicopathological and genomic parameters, and inversely correlating with PD-L1, making TROP-2 an ideal ADC target.
Keyword(s): Humans (MeSH) ; Carcinoma, Pancreatic Ductal: drug therapy (MeSH) ; Carcinoma, Pancreatic Ductal: pathology (MeSH) ; Carcinoma, Pancreatic Ductal: genetics (MeSH) ; Carcinoma, Pancreatic Ductal: metabolism (MeSH) ; Pancreatic Neoplasms: pathology (MeSH) ; Pancreatic Neoplasms: drug therapy (MeSH) ; Pancreatic Neoplasms: genetics (MeSH) ; Pancreatic Neoplasms: metabolism (MeSH) ; Immunoconjugates: therapeutic use (MeSH) ; Cell Adhesion Molecules: metabolism (MeSH) ; Female (MeSH) ; Male (MeSH) ; Middle Aged (MeSH) ; Aged (MeSH) ; Antigens, Neoplasm: metabolism (MeSH) ; Proto-Oncogene Proteins c-met: metabolism (MeSH) ; Biomarkers, Tumor: metabolism (MeSH) ; Biomarkers, Tumor: genetics (MeSH) ; Biomarkers, Tumor: analysis (MeSH) ; Aged, 80 and over (MeSH) ; Nectins: metabolism (MeSH) ; NECTIN4 ; TROP‐2 ; antibody–drug conjugates ; c‐MET ; pancreatic ductal adenocarcinoma ; spatial heterogeneity ; targeted therapy ; Immunoconjugates ; Cell Adhesion Molecules ; NECTIN4 protein, human ; Antigens, Neoplasm ; Proto-Oncogene Proteins c-met ; TACSTD2 protein, human ; Biomarkers, Tumor ; Nectins
; 
; Article Processing Charges ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; DEAL Wiley ; DOAJ Seal ; Essential Science Indicators ; Fees ; IF < 5 ; JCR ; PubMed Central ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection
|
The record appears in these collections: |
